Tenosynovial giant cell tumor.
Kager M, Kager R, Fałek P, Fałek A, Szczypiór G, Niemunis-Sawicka J, Rzepecka-Wejs L, Starosławska E, Burdan F.
Folia Med Cracov. 2022;62(2):93-107. doi: 10.24425/fmc.2022.141702.
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.
Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S.
Cancer Treat Rev. 2023 Jan;112:102491. doi: 10.1016/j.ctrv.2022.102491. Epub 2022 Dec 6.
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Gelderblom H, Bhadri V, Stacchiotti S, Bauer S, Wagner AJ, van de Sande M, Bernthal NM, López Pousa A, Razak AA, Italiano A, Ahmed M, Le Cesne A, Tinoco G, Boye K, Martín-Broto J, Palmerini E, Tafuto S, Pratap S, Powers BC, Reichardt P, Casado Herráez A, Rutkowski P, Tait C, Zarins F, Harrow B, Sharma MG, Ruiz-Soto R, Sherman ML, Blay JY, Tap WD; MOTION investigators.
Lancet. 2024 Jun 22;403(10445):2709-2719. doi: 10.1016/S0140-6736(24)00885-7. Epub 2024 Jun 3.
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ; ENLIVEN investigators.
Lancet. 2019 Aug 10;394(10197):478-487. doi: 10.1016/S0140-6736(19)30764-0. Epub 2019 Jun 19.
Malignant Tenosynovial Giant Cell Tumor: The True "Synovial Sarcoma?" A Clinicopathologic, Immunohistochemical, and Molecular Cytogenetic Study of 10 Cases, Supporting Origin from Synoviocytes.
Al-Ibraheemi A, Ahrens WA, Fritchie K, Dong J, Oliveira AM, Balzer B, Folpe AL.
Mod Pathol. 2019 Feb;32(2):242-251. doi: 10.1038/s41379-018-0129-0. Epub 2018 Sep 11.
Fine-needle aspiration cytology of diffuse type tenosynovial giant cell tumor with malignant trasformation and review of literature.
Shafi S, MacDonald W, Satturwar S.
Diagn Cytopathol. 2024 Oct;52(10):603-607. doi: 10.1002/dc.25338. Epub 2024 Jun 24.
Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.
Robert M, Farese H, Miossec P.
Front Immunol. 2022 Feb 21;13:820046. doi: 10.3389/fimmu.2022.820046. eCollection 2022.
Updates on the Treatment of Tenosynovial Giant Cell Tumor.
Chan AS, Katiyar V, Dy P, Singh V.
Hematol Oncol Stem Cell Ther. 2023 May 23;16(4):307-315. doi: 10.56875/2589-0646.1032.
Tenosynovial giant cell tumor: a case report.
Ansel S, Yan X, Chong P, Lo S, McCleery M, Mahendra A, MacDuff E, Cowie F, Nixon I, White J; Scottish Sarcoma Network.
J Med Case Rep. 2023 Oct 6;17(1):419. doi: 10.1186/s13256-023-04156-w.
Treatment updates on tenosynovial giant cell tumor.
Palmerini E, Staals EL.
Curr Opin Oncol. 2022 Jul 1;34(4):322-327. doi: 10.1097/CCO.0000000000000853.
